Febbo Phillip G.'s Form 4 filing
Veracyte, Inc. (VCYT) · filed Mar 4, 2026
- Accession no.
- 0001649245-26-000004
- Filed
- Mar 4, 2026
- Trade date
- Mar 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $485.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Febbo Phillip G.CIK 0001649245 | Officer (Chief Scientific & Med Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Common Stock | FTax withholdingDisposed | −6,035 | $36.01 | −$217,320.35 | 130,771 | Direct | |
| Mar 2, 2026 | Common Stock | SSaleDisposed | −13,425 | $36.16F3 | −$485,448 | 117,346 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents weighted average sales price. Sale prices for the transactions range from $35.78 to $36.65. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Referenced by the price of 1 transaction in Table I.